Telix Pharmaceuticals Limited
NASDAQ:TLX · NASDAQ Global Select
+$0.12 today
Vol 0.08M · Avg 0.20M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $212.5M |
| Receivables | $207.3M |
| Inventory | $55.5M |
| Other Current | $19.4M |
| Total Current Assets | $494.8M |
| PP&E (Net) | $173.2M |
| Goodwill | $298.1M |
| Intangible Assets | $590.0M |
| Long-term Investments | $55.6M |
| Tax Assets | $116.1M |
| Other Non-current | $43.2M |
| Total Non-current Assets | $1.3B |
| Total Assets | $1.8B |
Analysis
Selected assets total $1.8B for Latest. The largest visible component is Intangible Assets at $590.0M, about 33.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $212.5M -70.1% | $710.3M +476.4% | $123.2M +5.9% | $116.3M +427.9% | $22.0M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $207.3M +30.4% | $159.0M +99.9% | $79.5M +155.4% | $31.1M +49.4% | $20.8M | $533.8M | $399.4M | -$1.7B |
| Inventory | $55.5M +45.6% | $38.1M +120.4% | $17.3M +200.2% | $5.8M +67.0% | $3.5M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 | $0 +100.0% | -$7.7M -141.9% | $18.3M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $494.8M -46.1% | $918.6M +308.5% | $224.8M +29.8% | $173.2M +264.4% | $47.5M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $173.2M +218.8% | $54.3M +78.1% | $30.5M +61.9% | $18.8M +197.6% | $6.3M | $1.2B | $1.5B | $687.8M |
| Goodwill | $298.1M +179.5% | $106.6M +2100.3% | $4.8M -12.2% | $5.5M +34.7% | $4.1M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $590.0M +90.6% | $309.5M +195.3% | $104.8M +77.7% | $59.0M +5.8% | $55.7M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $55.6M +812.0% | $6.1M -50.3% | $12.3M +322.1% | -$5.5M | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $116.1M +148.3% | $46.7M +128.5% | $20.5M +122.1% | $9.2M | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $43.2M -42.1% | $74.6M +12627.3% | $586.0K +79.2% | $327.0K +108.4% | -$3.9M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $1.3B +113.4% | $597.9M +244.7% | $173.5M +98.6% | $87.4M +40.3% | $62.3M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $1.8B +16.8% | $1.5B +280.7% | $398.3M +56.0% | $255.4M +132.5% | $109.8M | $13.3B | $11.9B | $10.6B |
| Account Payables | $107.4M +56.3% | $68.7M +109.2% | $32.8M +95.4% | $16.8M +41.4% | $11.9M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $19.6M +3.4% | $19.0M +1869.9% | $964.0K +51.5% | $636.2K +3248.6% | $19.0K | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $48.6M +322.1% | $11.5M +57.2% | $7.3M | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $17.2M +52.8% | $11.2M +2.3% | $11.0M +122.6% | $4.9M -19.6% | $6.1M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $99.6M -9.2% | $109.7M +28.0% | $85.7M +83.5% | $46.7M +230.6% | $14.1M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $347.0M +4.9% | $330.9M +110.2% | $157.4M +84.0% | $85.6M +125.3% | $38.0M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $587.1M +6.4% | $551.8M +6622.1% | $8.2M +147.9% | $3.3M | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $94.1M +903.3% | $9.4M +139.3% | $3.9M -25.2% | $5.2M | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 -100.0% | $3.3M -73.0% | $12.2M -46.0% | $22.5M -2.3% | $23.1M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $35.7M -20.1% | $44.7M -25.6% | $60.0M +9.3% | $54.9M +27.0% | $43.2M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $801.6M +29.9% | $617.3M +571.1% | $92.0M +2.4% | $89.8M +31.7% | $68.2M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $1.1B +21.1% | $948.2M +280.2% | $249.4M +42.2% | $175.3M +65.2% | $106.2M | $14.7B | $3.7B | $9.6B |
| Common Stock | $719.0M +20.5% | $596.8M +33.7% | $446.3M +20.3% | $371.0M +117.1% | $170.8M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$231.5M -8.7% | -$213.0M +19.2% | -$263.7M +3.4% | -$272.8M -57.3% | -$173.5M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $134.8M -26.9% | $184.4M +647.3% | -$33.7M -85.6% | -$18.1M -479.0% | $4.8M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $622.3M +9.5% | $568.2M +281.6% | $148.9M +86.1% | $80.0M +3607.5% | $2.2M | $9.1B | $7.7B | $3.3B |
| Total Debt | $699.8M +20.3% | $581.4M +3233.0% | $17.4M +67.0% | $10.4M +311.4% | $2.5M | $724.2M | $410.6M | $399.4M |
| Net Debt | $487.2M +478.0% | -$128.9M -21.8% | -$105.8M +0.1% | -$105.9M -443.0% | -$19.5M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.89B
Belite Bio, Inc
NASDAQ:BLTE
$5.85B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.36B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$5.28B
Celcuity Inc.
NASDAQ:CELC
$4.19B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.67B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.27B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.70B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.96B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does TLX have?
Telix Pharmaceuticals Limited (TLX) reported $212.53M in cash and equivalents in fiscal 2025.
How much debt does TLX carry?
Telix Pharmaceuticals Limited (TLX) reported $699.77M of total debt, with net debt of $487.24M.
Explore More
Continue the stock analysis
Jump to another research area for this company.